World Journal of
Pharmaceutical and Life Sciences

NAVIGATING THE COMPLEXITY: CHALLENGES AND ADVANCEMENTS IN CAR T-CELL THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA

Dr. P. Dhivya Prasath*, Raveena Rajesh Kumar, J. Subiksha and K. Aishwarya

ABSTRACT

Chimeric antigen receptor (CAR) T cell therapy is a groundbreaking treatment that involves modifying a patient's T cells to target tumors, with notable success in hematologic malignancies such as non-Hodgkin lymphomas and acute lymphoblastic leukemia (ALL). This approach engineers T cells with CARs, enabling them to specifically identify and destroy cancer cells. While CAR T cell therapy has been highly effective against blood cancers, its application to solid tumors faces significant challenges. The therapy shows promise but is also associated with serious limitations, including cytokine release syndrome (CRS), neurotoxicity, and high costs, which restrict its accessibility. Ongoing research focuses on enhancing efficacy, minimizing side effects, and broadening the therapy's applicability to various cancers through combination treatments, innovative CAR designs, and improved manufacturing processes. The goal is to make CAR T cell therapy more effective and accessible to a wider range of patients.

[Full Text Article]   [Download Certificate]